PDCD1 and lymphoma: Our data reported herein, now provide compelling preclinical rationale for testing combinations of high-dose AA and anti-PD1 agents in patients with aggressive lymphomas such as diffuse large B cell lymphoma and also provide justification for testing this promising combination in the preclinical setting in other malignancies.